Product Details:
Strength | 0.5 mg |
Manufacturer | Cipla Ltd. |
Composition | Everolimus |
Brand | Rolimus |
Form | Tablet |
Treatment | Used for the prevention of organ rejection in transplant patients |
Shelf Life | 24 Months |
Packaging Size | 10 Tablets |
Medicine Type | Allopathic |
ROLIMUS 5MG contains Everolimus is an antineoplastic chemotherapy drug. This medication is classified as an mTOR kinase inhibitor. It reduces the blood supply to the tumour and slows down the growth and spread of cancer cells. This medicine is used to treat people with advanced kidney cancer and subependymal giant cell astrocytoma (SEGA) by slowing the growth and spread of tumour cells. It is also used as Prophylaxis of organ rejection in kidney and liver transplant.
Everolimus is a targeted therapy which works by targeting specific to the cancer cells, thereby decreasing side effects caused by unwanted damage to the healthy cells. It is a kinase inhibitor that inhibits mTor kinase. mTor kinase is an enzyme required for cell growth and survival and by blocking this enzyme, the medication prevents cell division and, in turn, tumor growth. The medication can also interrupt the development of blood vessels (angiogenesis) that supply with nutrients, which tumor need to grow.
Always take this medicine as instructed by your doctor.Avoid grapefruit juice while taking this medicine. Swallow this medicine whole and do not chew or crush it. ROLIMUS 5MG can develop mouth ulcers and sores. Your doctor might prescribe with a mouthwash, gel or other products. Before taking this medicine, consult your doctor if you have any ongoing medication for any underlying disease. Do not drive or handle any machines while taking this medicine may cause tiredness. It is not to be used in children or adolescents below 18 years of age. The most common side effects are chills (signs of infection), fever, coughing and wheezing, excessive thirst, high or low urine output, increased appetite with weight loss, tiredness and bleeding.